Navigation Links
Mayo Clinic detective work shows possible side effect in macular degeneration drug
Date:10/24/2011

ROCHESTER, Minn. -- Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

Sophie Bakri, M.D., had been treating patients in her clinic with Food and Drug Administration-approved ranibizumab (Lucentis), when she began noticing a change in some patients.

"I was treating patients and measuring pressures, and I was surprised to see that in some of these people, their intraocular pressure was higher, and they didn't have a diagnosis of glaucoma," Dr. Bakri says. "So, why did the pressure go up? Was it from the drug itself, or the actual injection? Is this real? You don't know if it's a fluke unless you go back and look at the clinical trials. I took a closer look at the pooled data."

Intraocular pressure (IOP) is a measure of fluid pressure inside the eye. Measured in millimeters of mercury (mm/Hg), IOP that is higher than normal or above baseline (higher than 21 mm/Hg) can indicate glaucoma.

Data from the two clinical trials in many ways held the answers to Dr. Bakri's questions, but she found that knowing what to look for helps.

MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization in Age-Related Macular Degeneration) evaluated drugs including Lucentis, for treatment of age-related and other forms of macular degeneration (AMD). Both were two-year studies with monthly injections of Lucentis, compared to a control group who did not receive the injection. Pooling the two studies, which followed the treatment of 1,125 eyes, Dr. Bakri was able to perform a more robust evaluation of IOP changes. Some patients received Lucentis and others unknowingly received "sham" or mimicked injections, or a laser treatment called verteporfin photodynamic therapy (PDT), which did not involve injection.

Dr. Bakri found what she suspected: a subset of patients had increased IOP.

"We still don't know if it goes up because of the drug or the pressure of the repeated monthly injections, or both," she says. The take-home finding: intraocular pressure should be monitored in eyes receiving ranibizumab.

"A greater proportion of eyes in the ranibizumab groups had IOP increases regardless of the presence or absence of pre-existing risk factors, such as history of glaucoma, suspicion of glaucoma, ocular hypertension or use of a glaucoma medication," Dr. Bakri says.

A small portion, 8 percent, of all eyes across treatment groups received glaucoma medications in the study. Importantly, none of the patients needed glaucoma surgery.

"Our analysis was surprising because the increase was so prevalent and highly statistically significant," Dr. Bakri says. "Lucentis is an excellent drug that works very well, but if we use a drug, we gain long-term experience, and that's where side effects start showing up.


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer
2. Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients
3. Timing for clinical trials for stem cell therapy in spinal cord injuries is right
4. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
5. Penn-developed online informed consent tool could boost number of patients in cancer clinical trials
6. Mayo Clinic study: multiple surgeries and anesthesia exposure
7. Cleveland Clinic to establish chair for preventive cardiology from Cleveland Foundation
8. European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE
9. Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds
10. Abiraterone acetate improves fatigue in prostate cancer patients, says international clinical trial
11. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... New York (PRWEB) , ... January 16, 2017 ... ... SightMD today announced the addition of Victor Giamos, MD to their ... of SightMD and Managing Partner at North Shore Eye Care, a division of ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... St. Louisans are well-aware of the following facts at present:, ... be having no effect on keeping this particularly bad strain of the flu away , ... sneezing, or sniffling , These facts are well-known among the team at ...
(Date:1/16/2017)... Beverly Hills, CA (PRWEB) , ... January 16, ... ... published a manuscript in the Aesthetic Surgery Journal , the official journal ... study he conducted on lower eyelid retraction surgery. The procedure is designed to ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all types ... to test for, as well. The money spent screening for and treating cancer in ... U.S. screen patients for cancer more than in any other country that has an ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 16, 2017 Transparency Market Research states ... Devices Market  held a huge share of 43% in 2015. ... frontrunners in the overall market, grabbing the undivided attention of ... across geographies, and strong product portfolio is expected to keep ... ...
(Date:1/16/2017)... , Jan. 16, 2017  Dovetail Genomics today announced ... and assembly service, which yields chromosome-scale genome assemblies. The ... a Dovetail-hosted workshop on Jan. 17 at the Plant ... San Diego . "We are thrilled ... launch of our Dovetail Hi-C offering," said Todd ...
(Date:1/16/2017)... 2017  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased ... , CFA to its Board of Directors. He is ... Asset Management LLC . He is also the Chief ... investment advisory firm with over $1.5 billion under management. ... in security analysis and portfolio management. He began his ...
Breaking Medicine Technology: